Peptide Purity Testing: A Declaration-First Evidence Matrix

Peptide purity testing is not one test and “purity” is not a complete description of the evidence. A reported chromatographic area percentage may describe one separation result, while identity, content, related substances, water, counterion, residuals, stability, and biological activity remain separate questions. A defensible review starts with the claim being made and then asks whether the method actually addresses that claim.

Begin with the declaration, not the instrument

Write the proposed statement in plain language before reading a report. “The named peptide was detected,” “the measured chromatographic profile contained a principal peak,” and “the container contains a stated amount” are different declarations. They require different evidence and should not be collapsed into a single purity label.

ICH Q2(R2), Validation of Analytical Procedures, describes validation characteristics in the context of an analytical procedure’s intended purpose. ICH Q14, Analytical Procedure Development, describes science- and risk-based development concepts. Neither guideline authenticates a supplier document or turns an unqualified result into a universal specification. ICH Q2(R2) official PDF and ICH Q14 official PDF.

A declaration-first evidence matrix

How to read the method’s intended scope

For each reported result, record the analyte or measurand, sample identity, method purpose, system suitability or control information that is actually shown, and the report’s stated limitations. Q2(R2) frames validation around characteristics such as specificity, accuracy, precision, and range when relevant to the intended analytical procedure. Those terms describe a method’s performance for its defined use; they do not mean that every report containing a percentage has demonstrated every characteristic.

Q14 places analytical procedure development in a lifecycle and risk-management context. That perspective is useful for asking whether the method was designed for the declaration under review. It does not supply acceptance limits for an unspecified research material, and it is not a substitute for the report, protocol, or laboratory’s own approval records.

Purity, identity, and content are different records

A purity result commonly expresses the relative signal assigned within the stated separation and integration scheme. Identity asks whether the material corresponds to the named peptide, sequence, modification, or salt form. Assay or content asks a quantitative question about the amount of the stated measurand. A report can support one of these statements while leaving the others open.

Related substances, water, counterions, and residual solvents are also separate declarations. They may require different sample preparation, detectors, reference materials, or calculations. If a document does not report a field, mark it as not reported. Do not infer absence from silence.

Build an orthogonal evidence set for one lot

For a single research-material lot, arrange the evidence by claim: identity record, chromatographic purity record, quantitative content record where available, and separate records for water, counterion, residuals, or stability when those questions matter. Keep the lot identifier, document version, test date, method name, and issuing laboratory attached to each record.

“Orthogonal” means that a second measurement addresses a different failure mode, not that two copies of the same percentage were collected. The combination must still be interpreted within each method’s stated scope. Missing or non-comparable fields should remain visible in the record rather than being replaced with a composite score.

Record gaps without inventing a pass/fail result

• State the exact declaration under review.
• Link the declaration to the method and document that report it.
• Mark identity, content, related-substance, water, counterion, residual, stability, and activity fields separately.
• Record the lot, document revision, test date, and issuing role where shown.
• Describe what the method cannot answer, including unmeasured or co-eluting components.
• Keep unresolved gaps as “not reported,” “not applicable,” or “needs confirmation,” rather than assigning an unsupported purity grade.

Where this page fits in the documentation set

How to Read a Peptide HPLC Record addresses version and file-context questions for an HPLC document. Third-Party Reports and Batch Traceability follows a report back to a lot, and COA and batch-record review covers the surrounding document set. This article answers a prior question: which declaration is being made, and what evidence would be needed before that declaration is written?

Compliance boundary

This framework is for reading analytical claims in research records. It does not provide laboratory instructions, instrument settings, acceptance thresholds, testing services, product guarantees, or purchasing advice. ICH guidelines are cited for their stated analytical-development and validation scope only.

Official references

• International Council for Harmonisation. Q2(R2): Validation of Analytical Procedures. Final guideline.
• International Council for Harmonisation. Q14: Analytical Procedure Development. Final guideline.

Research scope: This summary reports analytical-document concepts from the cited official references and does not provide medical, veterinary, dosing, administration, safety, or treatment guidance. It does not represent a product-use recommendation.